Jun 01, 2020
AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors
May 05, 2020
Chief Science Officer at NYU Langone Health Elected to the National Academy of Sciences
Apr 22, 2020
Targovax and Valo Therapeutics Enter Collaboration to Develop RAS Neoantigen Coating of ONCOS Viruses Using PeptiCRAd Technology
Feb 20, 2020
GeneTex Launches Novel Recombinant RAS (G12D Mutant) Antibody [HL10]
Jan 13, 2020
Revolution Medicines Presents Data from its SHP2 and Oncogenic RAS(ON) Programs at 6th AACR-IASLC International Joint Conference
Jan 13, 2020
Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing For Patients With Non-Small Cell Lung Cancer
Jan 07, 2020
Revolution Medicines to Present Preliminary Data from Phase 1 Clinical Trial of RMC-4630 at 6th AACR-IASLC International Joint Conference
Dec 17, 2019
Kanazawa University Research: Possible Strategy for Cancer Treatment Found in Nuclear Transport Proteins
Dec 11, 2019
Study Reveals Mechanisms that Help Pancreatic Cancer Cells Avert Starvation
Oct 30, 2019
The Discovery Of Amgen's Novel Investigational KRAS(G12C) Inhibitor AMG 510 Published In Nature
Oct 24, 2019
Sixth Element Capital and Cancer Research UK Beatson Institute Announce Major Collaboration to Develop Novel RAS Inhibitors
Oct 24, 2019
Oblique Therapeutics Will be Presenting at the Inaugural RAS- Targeted Drug Discovery Europe Summit in Vienna in February 2020
Oct 17, 2019
Mirati Therapeutics To Present Pre-Clinical And Initial Clinical Data For MRTX849, A KRAS G12C Inhibitor, At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
Sep 17, 2019
REVOLUTION Medicines Announces Dosing of First Patient in RMC-4630-02, a Phase 1b/2 Trial Combining RMC-4630 with a MEK Inhibitor
Aug 27, 2019
Machavert Pharmaceuticals Signs Exclusive License Agreement to Control RAL GTPase Inhibitors against KRAS Cancers
Aug 02, 2019
Sysmex Obtains Japanese Manufacturing and Marketing Approval for the First Blood-based RAS Mutation Testing for Colorectal Cancer
Jul 10, 2019
Jazz Pharmaceuticals Acquires Pre-clinical Pan-RAF Inhibitor Program from Redx Pharma
Jul 09, 2019
Mirati Announces Clinical Collaboration to Evaluate MRTX849 in Combination with SHP2 Inhibitor TNO155
Jul 09, 2019
REVOLUTION Medicines Closes $100 Million Financing to Advance Pipeline of Novel Therapies Addressing Frontier Targets in RAS-Dependent Cancers
Jun 03, 2019
Amgen Announces First Clinical Data Evaluating Novel Investigational KRASG12C Inhibitor AMG 510 At ASCO 2019